FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2583641516> ?p ?o ?g. }

• W2583641516 abstract "Abstract Mantle-cell lymphoma (MCL) is recognized as a distinct clinico-pathologic entity, accounting for 3–10% of all non-Hodgkin’s lymphomas, with median overall survival not exceeding 3–4 years. Patients with MCL are typically older adults with a male predominance and usually present with stage IV disease. The neoplastic cells are characterized as CD20+ CD5+ CD23−, with a t(11;14)(q13;q32) and cyclin D1 overexpression on immunohistochemistry. The current, most diffused regimens for the treatment of MCL include either R-CHOP or R-HyperCVAD, followed by autologous stem cell transplantation or observation, depending on the patient’s eligibility. However, considering that MCL is frequently diagnosed in elderly subjects with relevant co-morbidities, high dose chemotherapy or the use of drugs with potential cardiotoxicity, such as anthracyclines, may result not feasible in a significant proportion of patients. In this setting, recent data suggest that the proteasome inhibitor bortezomib is well tolerated and has significant single-agent activity in patients with MCL. Thus, we evaluated safety and efficacy of the RBC regimen, a 21-day cycle, anthracycline-free combination of rituximab (375 mg/m(2) on day 1), bortezomib (1.3 mg/m(2) on days 1, 4, 8, and 11) and hyper-fractionated cyclophosphamide (600 mg/m(2)/d given as a double, three-hour infusion on days 1–3) in “true” (≥ 75 year-old) elderly patients with advanced MCL. Diagnosis was made according to standard histological, phenotypic and molecular criteria. The results of an early analysis on feasibility in the first six patients enrolled (3 male, 3 female) are reported here. Mean age was 79.8 years (range 75–84). All patients had stage IV disease, evidencing extranodal localizations (n. 2) or marrow/leukemic involvement (n. 4). IPI score was 2 in three patients, 3 in two patients and 4 in one patient. Three patients received RBC as first line therapy, the others were treated at relapse after (R)-CHOP- like regimens. Hematological toxicities consisted in grade 1 (n. 2) and grade 2 (n. 1) thrombocytopenia, while one patient experienced grade 3 neutropenia, requiring G-CSF support. No extra-hematological toxicities higher than grade 1 were observed. Full doses of RBC were constantly administered. One patient, who presented with a WBC count > 200.000/μl, died during the first cycle due to progressive disease; another patient showed an initial response in extranodal sites and then progressed before the fourth planned cycle. The remaining four patients received six cycles: one patient achieved a partial response and three obtained a complete response, one of whom showing a molecular remission using PCR for t(11;14) bcl-1/IgH determination. All responders (66.6%) maintain their remission phase 7–10 months after the start of RBC treatment. Although very preliminary, these results indicate that RBC regimen is feasible, well tolerated and may be effective (including the possibility to obtain molecular response) in very elderly patients with advanced MCL. Larger and more mature data will be presented at the Meeting." @default.
• W2583641516 created "2017-02-10" @default.
• W2583641516 creator A5003998299 @default.
• W2583641516 creator A5018088213 @default.
• W2583641516 creator A5028283823 @default.
• W2583641516 creator A5038063975 @default.
• W2583641516 creator A5042609656 @default.
• W2583641516 creator A5044869604 @default.
• W2583641516 creator A5048125572 @default.
• W2583641516 creator A5061903335 @default.
• W2583641516 creator A5063836948 @default.
• W2583641516 creator A5064976355 @default.
• W2583641516 creator A5078816497 @default.
• W2583641516 creator A5085797041 @default.
• W2583641516 creator A5086094426 @default.
• W2583641516 creator A5090196156 @default.
• W2583641516 date "2007-11-16" @default.
• W2583641516 modified "2023-10-16" @default.
• W2583641516 title "Combination of Rituximab, Bortezomib and Hyper-Fractionated Cyclophosphamide (RBC) in “True” Elderly Patients with Advanced Mantle Cell Lympoma." @default.
• W2583641516 doi "https://doi.org/10.1182/blood.v110.11.4448.4448" @default.
• W2583641516 hasPublicationYear "2007" @default.
• W2583641516 type Work @default.
• W2583641516 sameAs 2583641516 @default.
• W2583641516 citedByCount "1" @default.
• W2583641516 countsByYear W25836415162017 @default.
• W2583641516 crossrefType "journal-article" @default.
• W2583641516 hasAuthorship W2583641516A5003998299 @default.
• W2583641516 hasAuthorship W2583641516A5018088213 @default.
• W2583641516 hasAuthorship W2583641516A5028283823 @default.
• W2583641516 hasAuthorship W2583641516A5038063975 @default.
• W2583641516 hasAuthorship W2583641516A5042609656 @default.
• W2583641516 hasAuthorship W2583641516A5044869604 @default.
• W2583641516 hasAuthorship W2583641516A5048125572 @default.
• W2583641516 hasAuthorship W2583641516A5061903335 @default.
• W2583641516 hasAuthorship W2583641516A5063836948 @default.
• W2583641516 hasAuthorship W2583641516A5064976355 @default.
• W2583641516 hasAuthorship W2583641516A5078816497 @default.
• W2583641516 hasAuthorship W2583641516A5085797041 @default.
• W2583641516 hasAuthorship W2583641516A5086094426 @default.
• W2583641516 hasAuthorship W2583641516A5090196156 @default.
• W2583641516 hasConcept C126322002 @default.
• W2583641516 hasConcept C141071460 @default.
• W2583641516 hasConcept C143998085 @default.
• W2583641516 hasConcept C2776364478 @default.
• W2583641516 hasConcept C2776694085 @default.
• W2583641516 hasConcept C2776755627 @default.
• W2583641516 hasConcept C2777478702 @default.
• W2583641516 hasConcept C2777525834 @default.
• W2583641516 hasConcept C2779050716 @default.
• W2583641516 hasConcept C2779338263 @default.
• W2583641516 hasConcept C2780653079 @default.
• W2583641516 hasConcept C2911091166 @default.
• W2583641516 hasConcept C71924100 @default.
• W2583641516 hasConcept C90924648 @default.
• W2583641516 hasConceptScore W2583641516C126322002 @default.
• W2583641516 hasConceptScore W2583641516C141071460 @default.
• W2583641516 hasConceptScore W2583641516C143998085 @default.
• W2583641516 hasConceptScore W2583641516C2776364478 @default.
• W2583641516 hasConceptScore W2583641516C2776694085 @default.
• W2583641516 hasConceptScore W2583641516C2776755627 @default.
• W2583641516 hasConceptScore W2583641516C2777478702 @default.
• W2583641516 hasConceptScore W2583641516C2777525834 @default.
• W2583641516 hasConceptScore W2583641516C2779050716 @default.
• W2583641516 hasConceptScore W2583641516C2779338263 @default.
• W2583641516 hasConceptScore W2583641516C2780653079 @default.
• W2583641516 hasConceptScore W2583641516C2911091166 @default.
• W2583641516 hasConceptScore W2583641516C71924100 @default.
• W2583641516 hasConceptScore W2583641516C90924648 @default.
• W2583641516 hasLocation W25836415161 @default.
• W2583641516 hasOpenAccess W2583641516 @default.
• W2583641516 hasPrimaryLocation W25836415161 @default.
• W2583641516 hasRelatedWork W2013342102 @default.
• W2583641516 hasRelatedWork W2551263070 @default.
• W2583641516 hasRelatedWork W2583641516 @default.
• W2583641516 hasRelatedWork W2745982028 @default.
• W2583641516 hasRelatedWork W2783172339 @default.
• W2583641516 hasRelatedWork W2810404518 @default.
• W2583641516 hasRelatedWork W3179327014 @default.
• W2583641516 hasRelatedWork W4250202452 @default.
• W2583641516 hasRelatedWork W857850315 @default.
• W2583641516 hasRelatedWork W2241811306 @default.
• W2583641516 isParatext "false" @default.
• W2583641516 isRetracted "false" @default.
• W2583641516 magId "2583641516" @default.
• W2583641516 workType "article" @default.